Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
AFT Pharmaceuticals (AFT NZ)
Watchlist
47
Analysis
Health Care
•
New Zealand
AFT Pharmaceuticals Limited develops, licenses, and sells pharmaceutical products. The Company offers medicines for allergy, cough, cold, and flu, eye care, pain management, and laxatives. AFT Pharmaceuticals serves customers worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Aft Pharmaceuticals
•
17 Jun 2022 00:19
•
Issuer-paid
AFT Pharmaceuticals - Re-acceleration leveraging its platform
Overcoming COVID-19 headwinds, AFT Pharmaceuticals reported strong FY22 year results, largely driven by management’s ability to leverage its broad...
Edison Investment Research
Follow
670 Views
Share
bullish
•
Aft Pharmaceuticals
•
25 May 2022 16:20
•
Issuer-paid
AFT Pharmaceuticals - Recovery driven by strong H222
AFT Pharmaceuticals (AFT) reported FY22 revenue of NZ$130.3m, up from NZ$113.1m in FY21, driven by improved performance in H222 (versus H122) amid...
Edison Investment Research
Follow
662 Views
Share
bullish
•
Aft Pharmaceuticals
•
22 Nov 2021 21:34
•
Issuer-paid
AFT Pharmaceuticals - 14% revenue growth despite COVID-19 headwinds
AFT Pharmaceuticals recently reported its results for H122. Operating revenue grew strongly by 14% year-on-year to NZ$55.5m, despite the impact of...
Edison Investment Research
Follow
687 Views
Share
bullish
•
AFT Pharmaceuticals
•
26 May 2021 14:36
•
Issuer-paid
AFT Pharmaceuticals - Growth in the face of a challenging environment
AFT Pharmaceuticals recently reported its results for FY21. Operating revenue grew strongly by 7% year-on-year to NZ$113.1m, driven mainly by 11%...
Edison Investment Research
Follow
535 Views
Share
bullish
•
AFT Pharmaceuticals
•
21 May 2020 20:00
•
Issuer-paid
AFT Pharmaceuticals - Solid FY20 results
AFT Pharmaceuticals recently reported its FY20 results. Operating revenue grew by a strong 24.0% year-on-year to NZ$105.6m as there was at least...
Edison Investment Research
Follow
34 Views
Share
First
Previous
3
4
5
6
7
8
9
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.7
x